Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 11/20 | 0.35 |
| ▸ | KDR | P35968 | 11/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | SIK1 | P57059 | 1/20 | 0.34 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.34 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3196988 | 1.00 | FGFR3 (0.35) | FGFR3KDRCNR2SIK1SIK2 | |
| SCHEMBL3383109 | 0.94 | KDR (0.35) | FGFR3KDRCTSC | |
| SCHEMBL3379613 | 0.90 | KDR (0.37) | FGFR3KDRCNR2SIK2SIK3 | |
| SCHEMBL3384486 | 0.89 | CCNE1 (0.37) | FGFR3KDRSIK1SIK2SIK3 | |
| SCHEMBL3383608 | 0.88 | SMN1; SMN2 (0.34) | FGFR3KDRSIK1SIK2SIK3 | |
| SCHEMBL3186146 | 0.87 | FGFR3 (0.36) | FGFR3KDRSIK1SIK2SIK3 | |
| SCHEMBL3186140 | 0.87 | FGFR3 (0.36) | FGFR3KDRSIK1SIK2SIK3 | |
| SCHEMBL3186881 | 0.87 | FGFR3 (0.33) | FGFR3KDRSIK1SIK2SIK3 | |
| SCHEMBL3186871 | 0.87 | FGFR3 (0.33) | FGFR3KDRSIK1SIK2SIK3 | |
| SCHEMBL3385891 | 0.86 | KDR (0.40) | FGFR3KDRWNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904494-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | LILLY CO ELI (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7666879-B2 | Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| EP-1904494-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006091671-A1 | IMIDAZO (1, 2-A) PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | KDR, FLT1, FLT4 | FGFR3 60/4885KDR 1/4885CNR2 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.